VLA1553, commercially known as Ixchiq, has received USFDA clearance and will be launched in India — which has seen high number of chikungunya cases — after ‘regulatory talks with DCGI’.
Trial of live-attenuated vaccine VLA1553 was conducted in US, with high seroprotection rates observed in participants up to 180 days after vaccination. Study published in 'The Lancet'.
Researchers from Chulalongkorn University in Thailand find that chikungunya strain identified in Thailand has mutations that originated in India and Bangladesh
Proposal to restart licensing is welcome, but Rs 300-crore minimum capital requirement could mean only handful of credit societies qualify, say sector executives
Overall, President Droupadi Murmu has approved Gallantry awards to 70 armed forces personnel, including six posthumous, on the eve of 77th Republic Day.
No nation other than China can negotiate one-on-one with Trump on an equal footing. That’s why the middle powers who so far formed the core of multilateral bodies now feel orphaned.
COMMENTS